125 related articles for article (PubMed ID: 2439199)
21. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M
Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108
[TBL] [Abstract][Full Text] [Related]
22. Exploring multidrug resistance using rhodamine 123.
Kessel D
Cancer Commun; 1989; 1(3):145-9. PubMed ID: 2639727
[TBL] [Abstract][Full Text] [Related]
23. Cell cycle-dependent translocations of a major nucleolar phosphoprotein, B23, and some characteristics of its variants.
Zatsepina OV; Todorov IT; Philipova RN; Krachmarov CP; Trendelenburg MF; Jordan EG
Eur J Cell Biol; 1997 May; 73(1):58-70. PubMed ID: 9174672
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D
Cancer Res; 1983 Aug; 43(8):3696-9. PubMed ID: 6861140
[TBL] [Abstract][Full Text] [Related]
25. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells.
Ling YH; Priebe W; Perez-Soler R
Cancer Res; 1993 Apr; 53(8):1845-52. PubMed ID: 8467504
[TBL] [Abstract][Full Text] [Related]
26. Overcoming drug resistance in cancer cells with synthetic isoprenoids.
Yamaguchi T; Nakagawa M; Shiraishi N; Yoshida T; Kiyosue T; Arita M; Akiyama S; Kuwano M
J Natl Cancer Inst; 1986 May; 76(5):947-53. PubMed ID: 3457980
[TBL] [Abstract][Full Text] [Related]
27. Differential effect of collaterally sensitive antimetabolites on P388 murine leukemia sensitive and resistant to adriamycin in vitro.
Satyamoorthy K; Deshpande SS; Chitnis MP
Neoplasma; 1989; 36(6):673-83. PubMed ID: 2515459
[TBL] [Abstract][Full Text] [Related]
28. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Rouse W; Riegler F
Cancer Res; 1984 Nov; 44(11):5056-61. PubMed ID: 6488165
[TBL] [Abstract][Full Text] [Related]
29. [The dynamic intracellular distribution of nucleolar protein B23 in the interphase and mitotic cells of mammalian cultures].
Zatsepina OV; Dudnik OA; Kudriavtsev IS
Tsitologiia; 1996; 38(7):758-64. PubMed ID: 9005649
[TBL] [Abstract][Full Text] [Related]
30. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Goldenberg GJ; Wang H; Blair GW
Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
[TBL] [Abstract][Full Text] [Related]
31. Evidence for a mutant allele of the gene for DNA topoisomerase II in adriamycin-resistant P388 murine leukemia cells.
Deffie AM; Bosman DJ; Goldenberg GJ
Cancer Res; 1989 Dec; 49(24 Pt 1):6879-82. PubMed ID: 2555055
[TBL] [Abstract][Full Text] [Related]
32. Sensitivity to anthracyclines in P388/dx leukaemia cells.
Bossa R; Dasdia T; Galatulas I; Zunino F
Anticancer Res; 1986; 6(5):1037-9. PubMed ID: 3099628
[TBL] [Abstract][Full Text] [Related]
33. [Characteristics of anthracycline-resistant strains of P388 leukemia].
Goncharova SA; Demidova NS; Shiriaeva OA; Shevtsova VN; Konovalova NP
Eksp Onkol; 1987; 9(4):42-7. PubMed ID: 3678124
[TBL] [Abstract][Full Text] [Related]
34. [Models of preclinical studies of anthracyclines].
Fizames C
Pathol Biol (Paris); 1987 Jan; 35(1):41-8. PubMed ID: 3550611
[TBL] [Abstract][Full Text] [Related]
35. Immunolocalization of phosphoprotein B23 in proliferating and non-proliferating HeLa cells.
Yung BY; Bor AM; Yang YH
Int J Cancer; 1990 Aug; 46(2):272-5. PubMed ID: 2200756
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
37. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
38. A murine model to evaluate the ability of in vitro clonogenic assays to predict the response to tumors in vivo.
Mirabelli CK; Sung CM; McCabe FL; Faucette LF; Crooke ST; Johnson RK
Cancer Res; 1988 Oct; 48(19):5447-54. PubMed ID: 3046738
[TBL] [Abstract][Full Text] [Related]
39. DNA breaks in P288 tumor cells in mice after treatment with daunorubicin and adriamycin.
Schwartz HS
Res Commun Chem Pathol Pharmacol; 1975 Jan; 10(1):51-64. PubMed ID: 1124321
[TBL] [Abstract][Full Text] [Related]
40. Modulation of doxorubicin efficacy in P388 leukemia following co-administration of verapamil in mini-osmotic pumps.
Slate DL; Fraser-Smith EB; Rosete JD; Freitas VR; Kim YN; Casey SM
In Vivo; 1993; 7(6A):519-23. PubMed ID: 8193270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
